Obiettivo The main objective of the CellUp business innovation project is to develop and commercialize the new disruptive in-lineanalytics sensor for upstream cell culture process that the biopharmaceutical industry needs for the quality and processcontrol during the phases of process development, scale-up and manufacturing of vaccines and antibodies for humanmedicines based on eukaryote cells culture.This new bioprocess analyser will be the first industrial sensor able to perform in-line quantification of the main nutrients andmetabolites during the mammalian cell culture inside the bioreactor.Today, cell cultures in bioreactors are only monitored in real time with temperature, PH and Oxygen density sensors. Thenegative consequences of such a limited control are huge in terms of batch failures, time consumed at each scale-up phaseand in terms of untapped production yield improvement.Our company, with its unique integrated SWIFTS technology has the opportunity to fix the above described problem byoffering a high performance miniaturized in-line Raman analyzer which can be implemented as an industrial GMP sensor.Based on the needs expressed by several major industrial actors, the company has already developed a first productsuccessfully evaluated and released end of 2016 under the name ProCellics.The objective of the CellUp project is to go a step further in the integration of the Raman analyser thanks to a newconfiguration of our technology, called SWITS-CD. We will also develop a new “standard addition method” technology and arelated software to provide an easy and robust way to implement the monitoring of the cell culture. The key to the success ofthis new methodology development is a cell culture activity carried internally by our company.The total accessible market is estimated at 750 M€ for a first equipment of the 20,000 biopharma industry bioreactors, allowing the emergence of a European leader with more than 300 job creation over 10 years. Campo scientifico natural sciencescomputer and information sciencessoftwareengineering and technologyenvironmental biotechnologybioremediationbioreactorssocial sciencessociologyindustrial relationsautomationengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsnatural sciencesphysical sciencesopticsspectroscopy Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Argomento(i) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Invito a presentare proposte H2020-SMEInst-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-2-2016-2017 Meccanismo di finanziamento SME-2 - SME instrument phase 2 Coordinatore RESOLUTION SPECTRA SYSTEMS Contribution nette de l'UE € 1 969 553,75 Indirizzo 13 CHEMIN DU VIEUX CHENE 38240 MEYLAN Francia Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Auvergne-Rhône-Alpes Rhône-Alpes Isère Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 1 969 553,75